Thrilled to share our latest publication on castration resistance published in @CellReports cell.com/cell-reports/fullte… Key Discoveries BCL2 a driver of early castration resistance. Crosstalk in AR-BCL2-PI3K signaling pathways. Venetoclax ENZ combo delated CSPC growth.

Presented at #ASCO26: Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM @ASCO

Absolutely practice changing!! One of the most stunning developments in the treatment of patients with metastatic pancreatic cancer !! It is one of the rare moments in oncology which you will always remember ! Like the imatinib, trastuzumab presentations @ASCO #ASCO26 @OncoAlert

Laboratory Visit of Dr. Richard Izquierdo Health & Science Charter School AP bio high sc student at #chakrabortlab @IcahnMountSinai @MountsinaiUro @TischCancer #stem . Discussing our reaseach with high school student to inspire them for their career goal.

Cancer survival in the U.S. just crossed 70%. It was 63% in the 1990s. That gap = 4.8M people alive today. This one chart captures survival gains across 29 cancer types. The wins are real. So is the unfinished work. ▪️CML: 31% → 72% ▪️Multiple myeloma: 32% → 62% ▫️Kidney: 59% → 82% ▫️Metastatic melanoma: 16% → 35% ▫️Childhood ALL: 80% → 92% But some cancers barely moved. Cervical cancer outcomes actually worsened. None of this is abstract progress, though. These are birthdays, grandkids, and years of life returned. This is what funded science does. Next time someone asks if cancer research works, show them this (full) chart. - - - - - Source: ACS Cancer Statistics 2026 · SEER · 𝘷𝘪𝘢 @Jori_health - - - - -

NIH is proudly prioritizing drug repurposing as a way to accelerate research while using resources efficiently. Watch for some outstanding examples of how we’ve applied gold standard science to find new ways existing therapies can benefit more patients now:

Emergence of BRCA Reversion Mutations in Prostate Cancer Prior to PARP Inhibitor Exposure: Clinical and Therapeutic Implications onlinelibrary.wiley.com/doi/… BRCA1/2🧬 reversion mutations, which restore BRCA function and confer PARP inhibitor resistance, were identified in advanced #ProstateCancer both after and without prior PARP inhibitor exposure. In this retrospective liquid biopsy study, 30% of PARP-naïve patients with BRCA reversions had received chemotherapy and radiation, suggesting DNA-damaging therapies may promote reversion and primary resistance, supporting earlier PARP inhibitor use. @DougLinMD @MaxMaomaoYe @OGjoerup @RyonGraf @RichardHuangMD @DouglasMab3lt @DrRanaMcKay @OncoAlert 🚨 @silkegillessen @AOmlin @weoncologists

Cancer statistics, 2026 - Siegel - 2026 - CA: A Cancer Journal for Clinicians - Wiley Online Library acsjournals.onlinelibrary.wi…

Come work with our team at PCF! cancercareers.org/jobs/48605…

Building a team and enjoying scientific discoveries, such an exciting 2025 and Best wishes for 2026, from #chakrabortylab @IcahnMountSinai @TischCancer @MountsinaiUro @PCFnews #CancerResearch #discovery #science #CancerResearcher #NewYork #HappyNewYear #2026

Happy Holidays from #chakrabortylab #holidayparty #lablife #sciencesndfun @TischCancer @IcahnMountSinai @MountsinaiUro

Its always exciting to learn from Dr. #greggsemenza #noblelaureate about #hypoxia. Great morning session of #7thinternationalprostatecancersymposium @IcahnMountSinai @TischCancer @MountsinaiUro @AshTewariMD

Another beautiful study published by Dr. Kyprianou and Dr. Nepali here at Mount Sinai Urology Department. Check eegk.github.io/publications/ for a free download link to this publication.

The most scary Halloween Costume for a researcher

Thrilled to share our good news: The Mount Sinai Tisch Cancer Center is now a NCI-Designated Comprehensive Cancer Center, affirming the depth of our cancer research and scientific discovery, clinical excellence, and commitment to health equity. bit.ly/3L5sF6X @theNCI

📺 WOW! Today President @JoeBiden rang the bell at Penn Medicine — new photos and videos shared by Ashley Biden capture the incredible moment. Ashley said her dad has been “so damn brave” during his treatment. It even looks like he brought flowers for his doctor — which is so Joe, always thinking of others. I absolutely love seeing this. No one is stronger in will and faith than #46. Let’s keep President Biden in our prayers as he continues to fight. 💙🙏🇺🇸

Challenge is (as almost always) the imperfect biomarker. Bland and open to pre-analytical variables. I’m sure a true measure of pathway functionality would push that needle further 😊.

Breaking news from #ESMO25👉Improved OS in high risk biochemical recurrent #ProstateCancer on with ENZA ADT vs ADT alone, HR: 0.59 (no OS benefit with ENZA monotherapy), 👏wonderful news for our pts👉congrats @SFreedlandMD @nealshore & the team. @OncoAlert @urotoday @PCF_Science